Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

121 results about "Airway disease" patented technology

Airway diseases -- These diseases affect the tubes (airways) that carry oxygen and other gases into and out of the lungs. They usually cause a narrowing or blockage of the airways. Airway diseases include asthma, COPD and bronchiectasis.

Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators

Provided herein are substituted pyrrolopyridine heterocycles and substituted pyrazolopyridine heterocycles, pharmaceutical compositions comprising said heterocycles and methods of using said heterocycles in the treatment of disease. The heterocycles disclosed herein function as kinase modulators and have utility in the treatment of diseases such as cancer, allergy, asthma, inflammation, obstructive airway disease, autoimmune diseases, metabolic disease, infection, CNS disease, brain tumor, obesity, asthma, hematological disorder, degenerative neural disease, cardiovascular disease, or disease associated with angiogenesis, neovascularization, or vasculogenesis.
Owner:SGX PHARMA INC

Methanocarba cycloakyl nucleoside analogues

The present invention provides novel nucleoside and nucleotide derivatives that are useful agonists or antagonists of P1 or P2 receptors. For example, the present invention provides a compound of formula A-M, wherein A is modified adenine or uracil and M is a constrained cycloalkyl group. The adenine or uracil is bonded to the constrained cycloakyl group. The compounds of the present invention are useful in the treatment or prevention of various diseases including airway diseases (through A2B, A3, P2Y2 receptors), cancer (through A3, P2 receptors), cardiac arrhythmias (through A1 receptors), cardiac ischemia (through A1, A3 receptors), epilepsy (through A1, P2X receptors), and Huntington's Disease (through A2A receptors).
Owner:HEALTH & HUMAN SERVICES GOVERNMENT OF THE UNITED STATES OF AMERICA THE REPRESENTED BY THE SEC DEPT OF

Process for the preparation and activation of susbstances and a means of producing same

The present invention relates to a process for the preparation and activation of a substance and a means for producing the activated substance. In particular, the invention relates to a method of treating a disease in a subject in need of such treatment, comprising the step of administering a substance or active agent which comprises one or more components which have been agitated such that a harmonic of between 20 to 50 Hz has been produced, in an amount effective to treat said disease, with the proviso that the disease is not an airway disorder.
Owner:GLOBAL ECOLOGICAL PRODS

Diagnostics and therapeutics for an obstructive airway disease

InactiveUS6746839B1Effectively prescribeHigh clinical benefitSugar derivativesMicrobiological testing/measurementObstructive airway diseaseDisease cause
Methods and kits for detecting polymorphisms that are predictive of a subject's susceptibility to developing an obstructive airway disease, such as asthma, as well as for determining the relative severity of the disease are described. Assays for identify therapeutics are also described.
Owner:INTERLEUKIN GENETICS

SUBSTITUTED PHENOXY AMINOTHIAZOLONES as estrogen related receptor-alpha modulators

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV

Treatment and diagnostic methods for hypersensitive disorders

The current standard of care for the treatment of allergic airway diseases include short and long acting beta-agonists, and inhaled or systemic corticosteroids, cromolyn and xanthines that all have the potential of detrimental side-effects. The present invention describes a new mechanistic protein-based therapeutic approach for the treatment of allergic airway disease and diseases associated with excessive Th2 pathology. The present invention relates to the surprising discovery that serum amyloid P (SAP) demonstrates a therapeutic affect in the treatment of hypersensitive disorders.
Owner:PROMEDIOR

Airway implant sensors and methods of making and using the same

InactiveUS20060185680A1OthrodonticsTeeth fillingImplanted deviceDrug-induced apnea
An airway implant device for maintaining and / or creating an opening in air passageways is disclosed. Methods of using the device are also disclosed. The airway implant device comprises a deformable element to control the opening of an air passageway. Preferably the deformable element is an electroactive polymer element. Energizing of the electroactive polymer element provides support for the walls of an air passageway, when the walls collapse, and thus, completely or partially opens the air passageway. Some embodiments of the invention include a sensor capable of sensing the possible occurrence of an apneic event and activating the deformable element of the airway implant device. Methods of treating airway disorders such as sleep apnea and snoring with the airway implant device are disclosed herein.
Owner:PAVAD MEDICAL

Method for treating airway disorders

A method for management of asthma and other respiratory conditions is disclosed. This method uses exhaled nitric oxide readings to measure airway inflammation, thereby allowing precise titration of medication. The present invention can also be used to measure patient compliance with prescribed treatment regimes.
Owner:AEROCRINE AB

Substituted phenoxy n-alkylated thiazolidinediones as estrogen related receptor-alpha modulators

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV

Method for Treatment of Inflammatory Disorders Using Triptolide Compounds

InactiveUS20070244080A1Inhibiting cytokine productionRelieve symptomsOrganic active ingredientsAntipyreticHepatic fibrosisTriptolide
Inflammatory disorders, including obliterative airway disease, renal fibrosis, diabetic nephropathy, and liver fibrosis are treated with immunosuppressive triptolide compounds, in particular triptolide compounds effective to inhibit TGF-β production in a patient afflicted with such a disorder.
Owner:PHARMAGENESIS

Composition for Prevention, Treatment, and Diagnosis of Chronic Inflammatory Airway Diseases

InactiveUS20080138913A1Obtained easily and correctlyEasy to usePeptide/protein ingredientsDisease diagnosisAlpha-enolaseDisease
A pharmaceutical composition for preventing or treating chronic inflammatory airway diseases comprising alpha-enolase protein as an active ingredient is provided. The present invention also provides a diagnostic composition and a diagnostic kit for diagnosing chronic inflammatory airway diseases comprising alpha-enolase protein. The present invention further provides a composition for screening a therapeutic agent for chronic inflammatory airway diseases, comprising one or more of alpha-enolase protein or autoantibodies to alpha-enolase obtained from patients with chronic inflammatory airway diseases, and a method for screening a therapeutic agent for chronic inflammatory airway diseases using this composition. The present invention still further provides methods for diagnosing, preventing or treating chronic inflammatory airway diseases using alpha-enolase protein.
Owner:JEON SOOK YEONG +1

Intraoral apparatus for treating upper airway disorders

A removable intraoral apparatus for improving airway patency is described. Wearing the apparatus alters the position, configuration and freedom of movement of the tongue, the muscles of mastication, as well as the pharyngeal and facial muscles. The apparatus is useful for correcting snoring and / or obstructive sleep apnea due to intermittent closures or partial obstructions occurring in the oropharynx during sleep. The apparatus of the invention can improve various types of airway disorders and improve oral functions by changing the position, configuration and freedom of movement of selected portions of the tongue and mouth, reducing the resistance to air flow in the mouth and pharynx, re-orienting and reprogramming the muscles of the mouth and tongue, and maintaining a proper oral systemic balance.
Owner:TNT LABS

Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists

InactiveUS20070276024A1Reduce the populationPrevents decrease in populationBiocideCompound screeningScreening methodTherapeutic effect
The present invention describes a method for treating a disease or condition associated with the activity of a G protein coupled receptor (GPCR) comprising administering an inverse agonist for the GPCR, alone or in combination with an agonist for the GPCR, to an organism with a disease or condition associated with the activity of the GPCR in a quantity and for a period that causes an increase in the population of spontaneously active GPCRs associated with that physiological function, thereby producing a therapeutic effect to ameliorate the disease or condition. This provides a basis for so-called “paradoxical pharmacology.” These methods can be used to treat pulmonary airway diseases, including asthma and chronic allergic rhinitis, among other diseases and conditions, including obesity. The present invention further describes a screening method for screening a compound for inverse agonist activity to a GPCR.
Owner:INVION LTD

Intraoral functional device for relieving obstructive sleep apnea syndrom, snoring and/or other airway disorders

An intraoral device (1) includes upper cooperating elements (2) adapted to cooperate with the upper jaw (4) and lower cooperating elements (3) adapted to cooperate with the lower jaw (5); a bracket (19) fixed in the cooperating elements (2,3), the bracket (19) supports a target (18) aiming at inducing mandibular advancement and attracting the tip of the tongue; the target (18) being centered, in a transverse plane, with regard to the cooperating elements (2,3). The device (1) further includes stimulating elements (17) for stimulation of the tongue muscles, preferably the genioglossus, involving reflex exploration of the stimulating elements (17) by the tongue. The device (1) may be used for relieving obstructive sleep apnea syndrome, snoring and / or other airway disorders.
Owner:PANTHERA DENTAIRE INC

System for monitoring a state of disease

The present invention relates to a device, a system and a method for measuring the lung function and the inhalation technique of a human subject, to facilitate the empowerment of patients to self-manage airway diseases, in particular asthma. The device according to the invention comprise a first part capable of measuring the time (s) and volume of air / time (v / s) exhaled from the human subject during a single inhalation, thereby providing a measurement of the lung function, and further comprising a second part capable of measuring the acceleration (m / s2) of air and volume of inhalation from the human subject during a single inhalation, thereby providing a measurement of the inhalation technique, the second part of the device further comprising means for applying metered resistance to the inhalation, the applied resistance impairing the acceleration (m / s2) of air and volume of inhalation from the human subject during the inhalation.
Owner:DARKET LONE

Ciclesonide for the treatment of airway disease in horses

The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative or salt thereof, for the treatment of airway disease in horses, such as pulmonary disease, preferably recurrent airway obstruction (RAO), Summer Pasture Associated Obstructive Pulmonary disease (SPAOPD), and inflammatory airway disease (IAD).
Owner:BOEHRINGER LNGELHEIM VETMEDICA GMBH

Truncated CMV promoters and vectors containing same

The present invention relates to nucleic acid molecules comprising certain truncated forms of the human cytomegalovirus (CMV) immediate-early enhancer-promoter, either alone or operably linked to transgenes of interest, including those encoding partially-deleted CFTR proteins. This invention further relates to vectors comprising these nucleic acid molecules and host cells transformed by such vectors. The nucleic acid molecules, vectors and transformed host cells of the present invention are useful for treating a variety of genetic, metabolic and acquired diseases, including inter alia cystic fibrosis (CF) airway disease.
Owner:NAT INST OF HEALTH REPRESENTED BY THE SEC OF THE DEPT OF HEALTH & HUMAN SERVICES NAT INST OF HEALTH +1

Method of treating airway diseases with beta-adrenergic inverse agonists

The use of β-adrenergic inverse agonists provides a new and highly efficient way of treating a number of pulmonary airway diseases, including asthma, emphysema, and chronic obstructive pulmonary diseases. In general, such a method comprises administering a therapeutically effective amount of a β-adrenergic inverse agonist to the subject to treat the pulmonary airway disease. Particularly preferred inverse agonists include nadolol and carvedilol. In addition, methods are described for long-term administration of such inverse agonists and for determining the suitability of patients for long-term inverse agonist therapy.
Owner:INVERSEON INC

Airway alkalinization as a therapy for airway diseases

The present invention relates to a method of treating asthma by raising the pH of the airways of an individual. The effect can be mediated directly by administering a pharmaceutically acceptable basic solution or alternatively, the effect can be mediated by enhancing the activity of glutaminase.
Owner:HUNT JOHN F +1

Use of quinazoline derivatives for the treatment of viral diseases

The present invention relates to the use of quinazoline derivatives, which show EGFR inhibitory activity, for the prevention and / or treatment of virus-induced diseases, preferably virus induced respiratory diseases and exacerbation in chronic airway diseases such as COPD or asthma.
Owner:BOEHRINGER INGELHEIM INT GMBH

Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses

The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention specifically relates to muscarinic antagonists (including long acting muscarinic antagonists (LAMAs)) for the treatment of airway disease, such as pulmonary disease, preferably recurrent airway obstruction (RAO), summer pasture associated obstructive pulmonary disease (SPAOPD), and inflammatory airway disease (IAD) in animals, preferably equines such as horses.
Owner:BOEHRINGER LNGELHEIM VETMEDICA GMBH

Inhibitors of cathepsin b

The present invention is directed to a method of using compounds of Formula (I) to inhibit Cathepsin B. Specifically the compounds of the present invention are useful as therapeutic agents for the treatment of tumor invasion, metastasis, Alzheimer's Disease, arthritis, inflammatory diseases such as chronic and acute pancreatitis, inflammatory airway disease, and bone and joint disorders, including osteoporosis, osteoarthritis, rheumatoid arthritis, psoriasis, and other autoimmune disorders, liver fibrosis, including liver fibrosis associated with HCV, all types of steatosis (including non-alcoholic steatohepatitis) and alcohol-associated steatohepatitis, non-alcoholic fatty liver disease, forms of pulmonary fibrosis including idiopathic pulmonary fibrosis, pathological diagnosis of interstitial pneumonia following lung biopsy, renal fibrosis, cardiac fibrosis, retinal angiogenesis and fibrosis / gliosis in the eye, schleroderma, and systemic sclerosis. The compounds of Formula (I) are also useful for treating subjects with both HCV and fibrosis in a mammal, particularly liver fibrosis, and subjects affirmatively diagnosed or at risk for both HCV and liver fibrosis.
Owner:VIROBAY INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products